Allogeneic HSCT represents the only curative option for patients with GATA2 mutation who develop MDS, and, importantly, may reverse other clinical features associated with the mutation [82].Both myeloablative and reduced intensity conditioning regimens have been successfully used as well as different donor types [30,82]. Here, GATA2 is linked to myelodysplastic syndrome.